NSPR News and Press, InspireMD Inc. From 03/26/24

TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of t...

2024-03-06 12:53:18 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips InspireMD (NASDAQ: NSPR ) just reported results for the fourth quarter of 2023. InspireMD reported earnings per share of -16 cents. This was above the analyst estimate for...

2024-03-06 11:30:12 ET InspireMD Inc. (NSPR) Q4 2023 Earnings Conference Call March 06, 2024, 08:30 AM ET Company Participants Charles Padala - Investor Relations, LifeSci Advisors Marvin Slosman - President and Chief Executive Officer Craig Shore - Chief Financi...

2024-03-06 07:08:49 ET More on InspireMD Seeking Alpha’s Quant Rating on InspireMD Historical earnings data for InspireMD Financial information for InspireMD Read the full article on Seeking Alpha For further details see: InspireMD GAAP EPS...

- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company’s ongoing U.S. Investigational Device Exemption (IDE) clinical trial, C-GUARDIANS, designed to support U.S. approval of CG...

Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...

2024-03-05 11:55:17 ET More on InspireMD Seeking Alpha’s Quant Rating on InspireMD Historical earnings data for InspireMD Financial information for InspireMD Read the full article on Seeking Alpha For further details see: InspireMD Q4 2023 ...

-Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke preve...

TEL AVIV, Israel and MIAMI, Feb. 12, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that the Company has appointed principal investigators (PIs) for its upcoming C...

TEL AVIV, Israel and MIAMI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that it has received CE Mark recertification under the European Union’s ...